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Abstract
Colorectal carcinoma (CRC) is a major cause of
morbidity and mortality in Western countries. It has
so far been molecularly defined mainly by alterations
of the Wnt pathway. We show here for the first time
that aberrant activities of the signal transducer and
activator of transcription STAT3 actively contribute to
this malignancy and, thus, are a potential therapeutic
target for CRC. Constitutive STAT3 activity was found
to be abundant in dedifferentiated cancer cells and
infiltrating lymphocytes of CRC samples, but not in
non-neoplastic colon epithelium. Cell lines derived
from malignant colorectal tumors lost persistent
STAT3 activity in culture. However, implantation of
colon carcinoma cells into nude mice resulted in
restoration of STAT3 activity, suggesting a role of an
extracellular stimulus within the tumor microenviron-
ment as a trigger for STAT activation. STAT3 activity in
CRC cells triggered through interleukin-6 or through a
constitutively active STAT3 mutant promoted cancer
cell multiplication, whereas STAT3 inhibition through
a dominant-negative variant impaired IL-6–driven
proliferation. Blockade of STAT3 activation in CRC-
derived xenograft tumors slowed down their develop-
ment, arguing for a contribution of STAT3 to colorectal
tumor growth.
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Introduction
Colorectal carcinoma (CRC) is a malignancy with a high and
increasing incidence and a high mortality. Almost 200,000
individuals are diagnosed annually with cancer of the colon
or the rectum in the United States alone, and nearly 50% of
these patients eventually dies of the disease [1]. Surgical
resection of tumors, chemotherapy, and radiotherapy consti-
tute current state-of-the-art treatment of CRC and have, in
combination, yielded improvements in cure and survival rates.
In recent years, there have been major advances in our
understanding of the molecular basis of this tumor and its
progression from adenoma to carcinoma. They hold potential
for translation into novel strategies for the treatment of CRC.
Many investigations focused on the dysregulation of the Wnt
pathway, whose components—adenomatous polyposis coli
(APC), b-catenin, and axin—are frequently mutated in colorec-
tal tumors. The consequence of these mutations is an accumu-
lation of nonphosphorylated b-catenin and, hence, constitutive
transcription of target genes such as cyclin D1, c-myc, c-jun,
and tcf1 (reviewed in Ref. [2]). Other mutations frequently
observed in colorectal cancer concern k-Ras as a trigger of
the growth-promoting mitogen-activated protein (MAP) kinase
pathway, tumor-suppressors p53 and Rb, and mediators of
transforming growth factor (TGF) b-signaling such as the
TGF-b type 2 receptor and transcription factor Smad4 (re-
viewed in Ref. [3]). In addition, defects in DNA repair genes
hmsh2, hmlh1, hpms1, or hpms2 have been implicated in the
tumorigenesis of CRC and appear to be associated with micro-
satellite instability [4,5]. Frequently observed dysregulation
concerns telomerase activity, which is present in colon cancer
but not in benign lesions [6].
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A mechanism explaining the causal connection between
oncogenic malfunction of signal mediators and tumorigene-
sis in self-renewing tissues as the colon is emerging for the
Wnt pathway. Constitutive activity of b-catenin signaling due to
single or multiple mutations in the APC and b-catenin gene re-
sults in dose-dependent differentiation defects in stem cells [7].
Stem cell development and embryonic patterning are
controlled by multiple routes of signal transduction, among
them the JAK-STAT (Janus kinase–signal transducer and
activator of transcription) pathway (reviewed in Ref. [8]).
Although the dysregulated activity of STAT factors 3, 1,
and 5 has been implicated in various cancers, no studies
have addressed it yet in the context of CRC.
STAT3, originally characterized as a mediator of
interleukin-6 receptor signaling [9], has extremely wide-
spread functions throughout the organism (reviewed in Ref.
[10]) and is the only embryonic lethal knockout within the
STAT family [11]. Apart from cytokine and growth factor
receptors, several viral or cellular oncogenes such as src,
fps, polyoma virus middle T-antigen, and sis are known to
activate STAT3 (reviewed in Ref. [12]). Some cancer-derived
cell lines depend on constitutively active STAT3 and undergo
apoptosis whenSTAT3 action is blocked [13,14]. Importantly,
a constitutively active artificial variant of STAT3 generated
by forced dimerization was shown to behave as an onco-
protein, causing tumorigenesis in nude mice [15]. Cell trans-
formation by aberrant STAT3 activity probably involves
upregulation of genes promoting cell cycle progression
(cyclin D1 and c-myc) and/or preventing apoptosis (bcl-xL,
mcl-1, and survivin) [15–18].
STAT3 is dysregulated in many cancers of the hemato-
poietic system (reviewed in Ref. [19]) as well as in various
solid tumors. Constitutive activity of STAT3 has been
reported in malignant tumors of the breast [14], head and
neck [20], skin [21], brain [22], and prostate [23]. It has also
been shown in some studies that STAT3 activation is sig-
nificantly associated with poor prognosis [20,24] and metas-
tasis [25]. The as-yet poorly characterized mechanistic
contributions of STAT3 to the respective tumor phenotype
are apparently not uniform and depend on the particular
tissue context. In head and neck tumors, for instance, STAT3
acts on the expression of cyclin D1 and is, thus, directly
involved in triggering the cell cycle [20]. In contrast, STAT3
activity in melanoma cells was found to downregulate cell
proliferation [26]. STAT3 may also promote the transformed
state of tumor cells by antiapoptotic signaling (i.e., through
upregulation of genes that counteract active cell death). In
cell lines from brain, skin, or breast tumors, overexpression of
antiapoptotic genes such as bcl-2, bcl-xL, and mcl-1 was
found to be associated with constitutive STAT3 activity, and
its experimental blockage could induce apoptosis [21,27,28].
Inhibition of signal mediators acting upstream of STAT3,
or the use of dominant-negative variants of STAT3 reduced
proliferation or enhanced apoptosis in various cell types
[24,20,21]. The most promising results with regard to STAT3
as a potential target for tumor treatment came from a study
on melanoma xenografts in nude mice. Introduction of a
dominant-negative STAT3 variant into preexisting tumors
by gene therapy inhibited tumor growth and led to tumor
regression [29].
Apart from STAT3, two other members of the STAT family
have also been associated with cancer. STAT5, originally
termed mammary gland factor, is not only frequently acti-
vated in blood cell tumors, but can also play a relevant role in
cellular growth control in solid cancers (e.g., of head and
neck or prostate) [30,31]. STAT1 is constitutively active
along with STAT3 in leukemias (e.g., Ref. [32]) and in solid
tumors. It appears to have a negative effect on tumor pro-
gression. In breast cancer, activation of STAT1 is a favorable
prognostic marker [33].
In this work, we have analyzed the status of STAT
activation in biopsies from colorectal cancer tissue, tumor-
derived cell lines, and xenograft tumors originating from
human colon carcinoma cells, and we present evidence for
an active role of STAT3 in oncogenesis.
Materials and Methods
Tumor Biopsies
Tumor biopsies were obtained from colorectal cancer
patients after approval of the study by the local ethical
committee. Patients were not treated with chemotherapy
prior to resection. Biopsies were snap-frozen in liquid nitro-
gen immediately after resection. Frozen blocks were disinte-
grated mechanically and whole cell extracts were prepared
by suspending the cells in a buffer containing 20 mM N-2
hydroxyethylpiperazine-N V-2-ethanesulfonic acid (Hepes;
pH 7.9), 400 mM NaCl, 1 mM EDTA, 20% glycerol, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 5 mg/ml
leupeptin, 0.2 U/ml aprotinin, 5 mM sodium orthovanadate,
10 mM NaF, and 5 M b-glycerophosphate, followed by three
to four freeze–thaw cycles in liquid nitrogen and on ice.
The extracts were cleared by centrifugation at 20,000g for
30 minutes at 4jC. Supernatants were subjected to protein
determinations followed by electrophoretic mobility shift
assays (EMSAs) and/or Western blot analyses.
Cell Lines and Cell Culture
Colon carcinoma cell lines HT-29, SW-480, and CaCo2
were purchased from the ATCC (Manassas, VA). The es-
tablishment and characterization of the low passage number
cell lines COGA 1, COGA 2, and COGA 3 have been
described previously [34]. All cell lines were cultured in RPMI
1640 medium containing 10% fetal calf serum, 200 mM
L-glutamine, 100 mM sodium pyruvate, and 1 mg/ml genta-
mycin. Cells were cultured in coated plasticware (Greiner
Labortechnik, Frickenhausen, Germany). For cytokine stimu-
lation, cells were incubated with 10 ng/ml IL-6 medium for
30 minutes. Cells were harvested at 80% confluency after
three PBS washes at 4jC. Whole cell extracts were pre-
pared from cell pellets as described above.
DNA Constructs and Retroviral Infection of Cells
A retroviral construct expressing wild-type mouse STAT3
was constructed by excision of the STAT3 coding sequence
546 STAT3 Activity in Colorectal Cancer Corvinus et al.
Neoplasia . Vol. 7, No. 6, 2005
from pME185m3 (obtained from Fabrice Gouilleux, Paris,
France) with EcoRI/Not I, and its ligation in the corresponding
sites of pMX-IRES-GFP (obtained from Toshio Kitamura,
Tokyo, Japan). The dominant-negative mutation in STAT3
(‘‘STAT3 d.n.’’; Y705F) was introduced using a site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufacturer’s instructions. The mutated sequence was
confirmed by sequencing and subcloned into the retroviral
vector as described above. The retroviral construct encoding
the constitutively active STAT3 mutant (‘‘STAT3 c.a.’’) was
obtained by transferring the STAT3 sequence form the pRC/
CMV2m3C-A (obtained from Jacqueline Bromberg, New
York, NY) into the pXM-IRES-GFP vector.
For retrovirus production, 293GPG packaging cells stably
expressing gag-pol and the VSV-G envelope protein [35]
were transiently transfected with retroviral vectors encoding
the different STAT3 constructs by the standard calcium
phosphate precipitation method. Four days after transfec-
tion, the growth medium containing virus particles was
filtered and used for infection. HT-29 cells were plated at
1  106 cells per well in six-well culture dishes 24 hours
before infection and incubated three times with a virus-
containing supernatant supplemented with 4 mg/ml polybrene
(Sigma, St. Louis, MO) for 24 hours. Infection efficiency was
analysed by measuring the GFP expression of the HT-29
cells by standard flow cytometric analysis.
EMSA
Whole cell extracts were prepared as described above
and subjected to Bradford protein determination. Protein
concentrations were adapted to equal levels. For analysis
of STAT1/STAT3 complexes, the SIEm67 STAT binding site
from the human c-fos promoter was used as a probe. Double-
stranded blunt-ended oligonucleotides were annealed
(5V-CATTTCCCGTAAATC-3V) and end-labelled using 32P-
g-ATP and T4 polynucleotide kinase to a specific activity of
10,000 cpm/fmol as described [15,36]. For STAT5 analysis,
the proximal STAT binding element (5V-AGATTTCTAG-
GAATTCAAATC-3V) from the bovine b-casein promoter was
employed in analogous ways [37]. Binding reactions were
performed by incubating 10,000 cpm of radiolabelled probe
with 20 mg of cell lysate for 30 minutes at room temperature.
For supershift reactions of STAT containing complexes, 2 mg
of antibodies to STAT1 (M22 recognizing the C-terminus;
Santa Cruz Biotechnology, Santa Cruz, CA), STAT3 (C-20 or
H-190, recognizing the N-terminus or C-terminus; Santa
Cruz Biotechnology), or Stat5 (C-17; Santa Cruz Biotech-
nology) was added to the binding reactions before EMSA
was performed. Samples were separated by electrophoresis
through 6% native polyacrylamide gels and analyzed by
autoradiography using BioMax-sensitive films (Kodak,
Rochester, New York).
Western Blot Analysis
Western blot analysis was performed as described
previously [36,37]. Briefly, 20 mg of whole cell extract
was solubilized in a gel loading buffer (62.5 mM Tris/HCl,
pH 6.8, 2% SDS, 25% glycerol, 1% phenol blue, and 5%
b-mercaptoethanol), boiled for 10 minutes, and separated on
a 7.5% or 10% acrylamide SDS gel. After protein transfer,
nitrocellulose membranes were blocked in NET-G buffer
for 1 hour. STAT3 P-Tyr705 (Cell Signaling Technology,
Beverly, MA) and STAT3-a (c-20; Santa Cruz Biotech-
nology) were incubated for 36 hours in a 1:1000 dilution.
Detection was performed with peroxidase-conjugated anti-
rabbit IgG (Roth, Karlsruhe, Germany) at a dilution of 1:
10,000 for 1 hour. Visualization was performed using an
Enhanced Chemiluminescence detection kit (Amersham,
Piscataway, NJ).
Immunohistochemistry and Laser Microscopy
Formalin-fixed, paraffin-embedded sections (5 mm) were
deparaffinized by subjecting them to two 5-minute changes
in 100% xylene and rehydrated by serial incubations in
100%, 96%, 80%, 70%, and 50% xylene, followed by Tris-
buffered saline (TBS). For antigen retrieval, sections were
autoclaved in 10 mM sodium citrate (pH 6.0) at 121jC for
20 minutes, cooled down to room temperature, and kept for
30 minutes in TBS. Furthermore, the sections were treated
with 3.0% H2O2 for 20 minutes to reduce endogenous
peroxidase activity. Unspecific binding sites were blocked
5% goat normal serum (Jackson Immunoresearch, West
Grove, PA) for 30 minutes. Sections were incubated over-
night with a 1:15 dilution for 2 hours (protocol i) or with a 1:50
dilution overnight (protocol ii) of the STAT3 P-Tyr705 anti-
body (Cell Signaling Technology). Signal detection was
achieved by two alternative procedures:
(i) In Figures 2 and 6, the streptavidin–enzyme
conjugate–based 4plus Universal Immunoperoxi-
dase Detection System (Biocarta, San Diego, CA)
using Jenchrom blue as chromogen (Mobitech,
Go¨ttingen, Germany) was applied according to the
manufacturer’s recommendations. Color develop-
ment time was in the range of 8 to 12 minutes.
Single-photon laser scanning microscopy was per-
formed with an LSM 310 (Carl Zeiss, Jena, Germany)
in transmission mode using an argon ion laser
at 488 nm. The Zeiss objective Plan-NEO FLUAR
63/1.30 oil was employed at a scanning time of
30 seconds. The nonprocessed grey values of typi-
cal transmission images were converted to inverted
values and then further processed to obtain red–
green–blue images out of 3  28 color values. The
chosen false color table was stored as a look-up
table and finally saved as a TIFF file [38].
(ii) In Figure 7, detection was performed using the Super
Sensitive Detection System by BioGenex (San
Ramon, CA) and AEC as chromogen. Microscopic
pictures were taken by using an Axioskop microscope
and Axiovision 4.2 software (Carl Zeiss).
Long-Term Cell Proliferation Assay
Aliquots of 105 cells were suspended in 2ml of RPMI 1640
medium supplemented as described above and allowed to
STAT3 Activity in Colorectal Cancer Corvinus et al. 547
Neoplasia . Vol. 7, No. 6, 2005
adhere in individual wells of six-well cell culture plates. They
were grown in the absence or presence of 20 ng/ml IL-6 for
up to 9 days. Medium with or without cytokine was changed
every 2 days. At intervals, cells from individual wells were
detached from the plastic surface in 0.5 ml of 0.05% trypsin/
0.02% EDTA (Biochrom, Berlin, Germany) for 2 minutes at
37jC before 1.5 ml of medium was added to restore the
original volume. Aliquots of cell suspensions were counted
using a Neubauer chamber and numbers of cells were
extrapolated to the total volume of the culture.
Xenograft Experiments
Aliquots of 105 HT-29 cells were suspended in a volume of
100 ml of PBS and injected subcutaneously into the neck
and (optionally) right and left flank (n = 2–4 per animal) of
male 5– to 8-week–old athymic Hsd:NMRI-nu/nu mice
(Harlan, Indianapolis, IN). Animals were kept under PF iso-
lation conditions and standard diet. The experimental end-
point was 21 days after tumor cell application and the animals
were sacrificed. If applicable, tumor sizes were measured
with the aid of a ruler and were calculated within a group as
arithmetic means with standard error of the mean (SEM). For
statistical analysis, the SigmaStat software (Systat, Erkrath,
Germany) was used. Differences were identified with Stu-
dent’s t test and considered significant at P < .05. All oper-
ations on live animals were performed under isoflurane
anesthesia (CuraMed Pharma, Karlsruhe, Germany).
For biochemical and immunohistologic analyses, tumor
specimens were further treated analogous to the human
biopsies.
Results
STAT3, STAT1, and STAT5 Are Constitutively Active
in Colorectal Cancer Tissue
Thirty-two colorectal tumor biopsies were obtained in
the course of tumor resections and subjected to the analysis
of STAT activity. The patients were staged according to
operation and pathologic findings with UICC TNM classifi-
cation: 11 in stage T2, 16 in stage T3, and 5 in stage T4.
Regarding the differentiation grade, 29 tumors were clas-
sified G2, two as G3, and one as G4. The surgical speci-
mens were investigated for their status of STAT activity
by EMSA. Figure 1A shows a representative selection of
tumor tissue samples tested for the formation of protein
complexes on the high-affinity DNA binding element for
STAT3 and STAT1, the SIEm67 site originating from the
human c-fos promoter.
In the majority of cases, one, two or three distinct specific
DNA–protein complexes were resolved. To define the iden-
tity of the individual complexes, all tumor samples were
analyzed by supershift analysis employing antibodies to
either STAT3 or STAT1. These experiments revealed that
the uppermost complex contained STAT3 and the lowermost
one contained STAT1, respectively. The intermediate com-
plex contained both STAT3 and STAT1, hence representing
a heterodimer of the two factors.
Next, we addressed the status of STAT5 activation.
Lysates from all 32 biopsies were tested for STAT binding
to the proximal STAT5 cognate element from the bovine
b-casein promoter. Figure 1B shows the result for a repre-
sentative selection of biopsies. To verify the identity of the
complex observed in about half the samples analyzed, a
DNA binding experiment were performed in the presence or
absence of a specific antibody to STAT5. Antibody-induced
Figure 1. Analysis of STAT activity by EMSA in extracts of colorectal car-
cinoma biopsies. (A) Extracts from colorectal tumor tissue samples (1–5) were
incubated with the double-stranded 32P-labelled SIE m67 STAT binding site.
Complexes were resolved on a 6% native polyacrylamide gel and visualized by
autoradiography. The identity of STAT-containing complexes was determined
by including specific antibodies in the binding reactions as indicated. According
to the results from the supershift experiments, positions of the specific STAT
complexes are indicated by arrows. (B) Extracts from colorectal tumor biopsies
(1–7) were analyzed for the formation of DNA–protein complexes on the
32P-labelled proximal STAT5 binding element from the bovine -casein
promoter. A representative tumor tissue extract (6) was subjected to a
supershift experiment by simultaneous incubation with a STAT5-specific
antibody as indicated. (C) Incidence of persistent STAT activity in the colorectal
tumor samples investigated in this work. Bars represent the respective
numbers of biopsies (from 32 individual colorectal tumors) positive for the
indicated STAT activity (activities) as analyzed by EMSA.
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disappearance of the specific DNA–protein complex and
the occurrence of a supershift band confirmed the presence
of activated STAT5.
Figure 1C summarizes STAT activity data obtained
with the 32 colorectal tumor biopsies under investigation.
Notably, 29 of 32 examined tumor samples showed STAT3
DNA binding activity. For STAT1 and STAT5, the respective
findings were 23/32 and 15/32. In many tumor samples,
simultaneous activation of more than one STAT was ob-
served. All samples with activated STAT5 also contained
constitutive STAT3 activity. In 10 of 32 samples, all three
STAT factors analyzed were found to be activated. There
was no striking correlation between tumor stage and the
respective STAT activity pattern. Of the T2 tumors investi-
gated, 10/11 were positive for STAT3, 6/11 for STAT1, and
5/11 for STAT5. For T3 tumors, the figures were STAT3:
16/16, STAT1: 14/16, and STAT5: 6/16. Results for T4 tu-
mors were: STAT3: 2/5, STAT1: 3/5, and STAT5: 1/5.
STAT3 was the STAT protein with the highest incidence
of constitutive activity in colorectal cancer biopsies.We there-
fore concentrated on it and analyzed its phosphorylation
state in tumor tissues both by Western blot analysis and
immunohistology. Figure 2A shows a Western blot analysis
of 12 representative tumor tissue lysates with an antibody
specific for STAT3 phosphorylated on Tyr705. In all samples
that had been positive for STAT3 DNA binding, signals from
phosphorylated STAT3 were observed. The identity of the
bands as STAT3 was confirmed by reprobing the blots with
anti-STAT3 (Figure 2B).
We addressed by immunohistochemistry, using an anti-
body to phospho-STAT3, which cell types within the tumor
are responsible for biochemically detected signals of acti-
vated STAT3 in the tumor specimens. Five representative
STAT3-positive tumor samples were subjected to this kind of
analysis and yielded similar results. Figure 2B shows sec-
tions from one tumor that were stained with hematoxilin and
eosin (H&E) (A) or antibody to phospho-STAT3 (B), respec-
tively. STAT3 is predominantly active in the transformed cells
of dedifferentiated epithelium and, thus, is massively abun-
dant in their nuclei. Signals are only apparent to a much
lesser extent in the epithelium of neighboring non-neoplastic
intestinal crypts. This result rules out the possibility that
STAT3 activity in the biopsies is mainly the result of lympho-
cyte function and inflammatory processes. It rather, together
with the biochemical data, indicates an involvement of
STAT3 in the development or maintenance of the cancerous
cell state in the intestinal epithelium.
Once Established in Culture, Colon Cancer Cells Lose
Constitutive STAT Activity
Having observed strong STAT activation in malignantly
transformed colon epithelium cells, we employed cell lines to
study the origin and consequences of this activity. First, three
established human colon carcinoma cell lines were analyzed
for STAT3 expression and specific DNA binding activity in
comparison with a clinical tumor specimen. All three cell lines
investigated showed STAT3 expression to a level compa-
rable with tumor tissues (Figure 3A).
Interestingly, and in striking contrast to the findings with
surgical tumor specimens, neither HT-29 nor CaCo2 or
SW480 cells showed any constitutive binding of STAT3 to
the SIE m67 STAT binding element (Figure 3B, leftmost
lanes of the respective panels). We therefore asked if
cytokines are involved in the activation of STAT3. Cells were
stimulated with various cytokines known to trigger STAT3
through the shared gp130 cytokine receptor chain. Oncos-
tatin M, leukemia-inhibitory factor, and interleukin-11 did not
evoke any detectable STAT3 activity (data not shown). In
contrast, IL-6 induced profound STAT3 activity in all three
colon carcinoma cell lines tested as indicated by specific
supershifting with the STAT3-specific antibody (Figure 3B).
Because persistent activities of STAT3 and STAT1 were
found together in many tumor samples investigated (com-
pare Figure 1), we also addressed if STAT1 was inducible by
cytokine stimulation. As shown in Figure 3C, interferon-g
induced specific DNA binding of STAT1 in all three colon
carcinoma cell lines. These data suggest that constitutive
STAT activity in cancerous colon epithelial cells is a conse-
quence of receptor activation by extracellular stimuli.
Figure 2. Analysis of STAT3 tyrosine phosphorylation in colorectal cancer
tissue. (A) Examination of lysates from tumor biopsies for activated STAT3 by
Western blot analysis. Samples were separated by PAGE, transferred to
nitrocellulose, and probed with an antibody specifically recognizing STAT3
phosphorylated on tyrosine 705 (top). Comparable loading of the lanes and
identity of STAT3 was confirmed by reprobing the blot with anti-STAT3
(bottom). (B) Histologic examination of a colorectal tumor sample for STAT3
activity. Sections from a representative tumor biopsy were stained with
hematoxylin/eosin (top) or immunoreacted with antibody to phospho-STAT3
(bottom). Sections showing differentiated normal cells in crypt structures or
dedifferentiated tumor tissues, respectively (arrows), were treated with an
antibody specific for STAT3 phosphorylated at tyrosine 705. As a control for
antibody and detection specificity, a typical section was stained with
peroxidase-coupled secondary antibody without prior treatment with anti-
pSTAT3 Tyr 705 (bottom right).
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The striking differences with regard to constitutive STAT3
activity between CRC biopsies and colon cancer cell lines
prompted us to include in this study low passage cell lines
that have been shown to closely mirror many properties of
the original tumors (e.g., phenotype, markers, genetic
changes) [34]. Three COGA cell lines, derived from colorec-
tal tumors of different grades, were examined for specific
DNA-binding of STAT3 by EMSA experiments and com-
pared with their respective parental tumors (Figure 4). First,
we studied clinical biopsies histologically. Representatives
of serial sections were examined by methylene blue stain-
ing. To make sure that the succeeding biochemical analysis
reflects the properties of actual tumor tissues, only portions
of the biopsies with obvious cancerous characteristics
(Figure 4A) were processed further. Regarding their con-
stitutive STAT activity status, biopsies from the tumors that
had given rise to cell lines COGA 1, 2, and 3 were found re-
presentative for the spectrum of tumor samples previously
analyzed (Figure 4B): The COGA 2 and 3 tumors showed
STAT3 activity as proven by antibody supershifts; the COGA
1 and 3 tumors revealed a faster migrating complex, which,
in analogy to Figure 1, represents STAT1. Figure 4C shows
that, despite the preservation of various other properties,
all three COGA lines examined did not exhibit constitutive
but only IL-6– inducible STAT3 activity. Extending the find-
ings presented in Figure 3, these results demonstrate that
tumor-borne constitutive STAT3 activity is consistently lost
on cultivation of colon carcinoma cell lines and regained by
cytokine stimulation.
STAT3 Drives Accelerated Proliferation in Colon
Carcinoma Cells
To address the possible functional involvement of STAT3
in the malignant transformation of colon epithelium cells, we
introduced a STAT3 cDNA as well as a constitutively active
and a dominant-negative derivative into the colon carcinoma
cell line HT-29 by retroviral infection. The constitutively
active STAT3 construct (‘‘STAT3 c.a.’’) had been generated
by introduction of a disulfide bridge, which forces the forma-
tion of stable dimers [15]. A dominant-negative STAT3
derivative (‘‘STAT3 d.n.’’) was constructed by replacing
Tyr705 with a Phe residue. Because the retroviral vector
encoded GFP, infection efficiencies could be checked by
FACS analysis for fluorescence and were routinely above
70% (data not shown). Expression of the heterologous
STAT3 proteins as well as tyrosine phosphorylation in re-
sponse to IL-6 stimulation was analyzed by Western blot
analysis (Figure 5A). The introduction of a wild-type STAT3
cDNA into HT-29 cells led to a robust overexpression of the
protein in comparison to parental cells and, concomitant with
the high abundance of STAT3, to a certain degree of
constitutive tyrosine phosphorylation. Tyrosine phosphoryla-
tion of STAT3 in response to incubation with IL-6 was
enhanced further only to a limited extent, probably due to
saturation of the IL-6 receptor system.
STAT3 c.a. and STAT3 d.n. were also expressed to
higher levels as the endogenous STAT3 on retroviral gene
transfer. STAT3 c.a. was phosphorylated in response to IL-6
stimulation to a lesser degree than wild-type STAT3. This
effect may be due to a somewhat poorer association of
STAT3 c.a. with the phosphorylated gp130 receptor chain
and/or impaired accessibility of the phosphorylation site for
the JAK kinase. Alternatively, negative feedback regulation
in stably transfected HT-29 cells might limit further enhance-
ment of STAT3 activity in the presence of the already active
Figure 3. Analysis of the STAT activity status in colon carcinoma cell lines. (A)
Western blot analysis (top) and EMSA analysis (bottom) of cell lines HT-29,
CaCo2, and SW 480. A STAT3-positive tumor sample (compare Figure 1)
served as a positive control. STAT3 expression was tested by subjecting cell
extracts to a Western blot probed with anti-STAT3. STAT3 activation was
analyzed by assaying for the formation of specific complexes on the SIE m67
DNA binding site. (B) Test for IL-6– inducible activation of STAT3 in cell lines
HT-29, CaCo2, and SW 480. Cells were either left untreated or incubated with
10 ng/ml IL-6 for 30 minutes as indicated. Lysates were subjected to an EMSA
using the m67 element as a probe. The identity of STAT3-containing com-
plexes was verified by supershift experiments employing an antibody to
STAT3 as indicated. Positions of STAT3 and STAT3–DNA complexes are
marked with arrows. (C) Test for IFN-c– inducible activation of STAT3 in cell
lines HT-29, CaCo2, and SW 480. Cells were either left untreated or incubated
with 10 ng/ml IFN-c for 30 minutes as indicated. Lysates were analyzed as in
(B), using an antibody to STAT1 for supershift experiments as indicated.
Positions of STAT1 and STAT1–DNA complexes are marked with arrows.
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Figure 4. Comparative analysis for STAT3 activity in colon carcinoma tissue and low passage colon cell lines derived from the respective tumors. (A) Histologic
representation (methylene blue staining) of sections from tumors that were analyzed for STAT3 activity in (B) and gave rise to the COGA cell lines studied in (C).
(B) EMSA of samples from tumors that gave rise to the COGA cell lines studied in (C). The SIE m67 STAT binding element was used as a probe; supershift
experiments were performed by employing an antibody to STAT3 as indicated. Arrows mark the positions of the respective complexes. Only portions of the
biopsies were processed for sample preparation that had previously been confirmed as cancerous by histologic examination of flanking sections (compare A). (C)
EMSA analysis of cell lines originating from the tumors assayed in (A) and (B). Cells were either left quiescent or stimulated with 10 ng/ml IL-6 before lysis and
treatment as in (B).
Figure 5. Expression and activation of heterologous STAT3 variants in HT-29 cells and effects of STAT3 activity on cell proliferation. (A) Western blot analysis
of tyrosine phosphorylation (top) and expression (bottom) of retrovirally introduced STAT3 variants in HT-29 cells. Cells were either left untreated or incubated with
10 ng/ml IL-6 for 30 minutes as indicated, lysed, and probed with antibody to phosphorylated STAT3 (top) or STAT3 (bottom), respectively. (B) Proliferation of HT-29
derivatives expressing constitutively active or dominant-negative STAT3 variants. Samples of 5  10 4 cells of each cell line were seeded into individual wells of six-
well cell culture plates in a volume of 2 ml. Medium was changed every 2 days. Where indicated, IL-6 was present in the medium at a concentration of 20 ng/ml
throughout the entire cultivation period. After 3, 6, and 9 days, aliquots were counted using a Neubauer chamber and cell numbers were extrapolated to the total
culture volume. Results are from four equivalent experiments. (C) Proliferation of COGA 1 cells in dependence of IL-6 stimulation. The experiment was performed
as described under (A) with the following variations: individual cultures were started at a cell number of 2  104; cell numbers were determined after cultivation for
3 and 6 days. Results are from four independent experiments.
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artificial dimer. STAT3 d.n. entirely blocked IL-6–dependent
phosphorylation of endogenous STAT3.
We then analyzed the effects of the heterologous
STAT3 constructs on the proliferative behavior of the
HT-29 derivatives. The development in cell number was
monitored over a cultivation period of 5 days (Figure 5B).
The presence of IL-6 in the medium resulted in faster cell
proliferation, suggesting an involvement of gp130-triggered
JAK/STAT signaling in growth control. Confirming this no-
tion, expression of STAT3 c.a. led to a profound acceleration
of cell proliferation, whereas expression of STAT3 d.n.
resulted in a significant decrease in the proliferation rate.
Infection of HT-29 cells with the empty retroviral GFP vector
had no significant effect on cell proliferation (data not
shown). These results show that STAT3 promotes cell
division and proliferation of the colon carcinoma cell line,
HT-29. To exclude the possibility that these findings are the
consequence of specific properties of the HT-29 cell line, we
studied the influence of IL-6 on the proliferative behavior of
COGA 1 cells. We observed a strong stimulatory effect of
IL-6 on cell division (Figure 5C), which, as recent transfection
experiments with COGA cell lines show, is mediated by
STAT3 (S.A.T., unpublished data).
Constitutive STAT3 Activity Is Restored in Tumors
Derived from a Colon Carcinoma Cell Line
A xenograft experiment was performed to further analyze
the differences between colon carcinoma cells in culture and
in the tumor context with regard to STAT3 activity. A total of
105 HT-29 cells were injected into immunodeficient nude
mice subcutaneously. All eight injected animals developed
tumors that were subsequently analyzed for STAT3 activity.
The EMSA experiment shown in Figure 6A indicates that the
HT-29–derived tumors had regained constitutive DNA bind-
ing activity in comparison to the cells used for the injection.
Specific supershifting of the band appearing in all tumors
with an antibody to STAT3 confirmed its identity as a STAT3-
containing complex. Histologic examination of the tumors
revealed the formation of crypt-like structures, which, on
staining with an antibody to tyrosine-phosphorylated STAT3,
displayed abundance and nuclear localization of activated
Figure 6. Determination of STAT3 acticity in HT-29 xenograft tumors. (A) Left:
Test by EMSA for the formation of specific complexes on the SIE m67 STAT
recognition element. Extracts of HT-29–derived tumors from nudemice (1–4)
were incubated with the radiolabelled probe and analyzed by native PAGE and
autoradiography. Right: Identification of STAT3 in the DNA–protein complex
from tumor ‘‘1’’ by incubation with a specific anti-STAT3 antibody as indicated.
Positions of STAT3-containing complexes and the antibody-dependent
supershifted complex are marked by arrows. (B) Histologic examination of
an HT-29–derived xenograft tumor for STAT3 activity. Sections from a rep-
resentative tumor induced by injection of HT-29 cells into nude mice were
stained with hematoxilin/eosin (top) or immunoreacted with an antibody
specific for STAT3 phosphorylated at tyrosine 705 (bottom). Typical sites of
crypt-like structures and tumor tissues with substantial nuclear concentration
of activated STAT3 are indicated by arrows.
Figure 7. Influence of a dominant-negative STAT3 variant on the growth of
HT-29 xenograft tumors. (A) Size of explanted tumors from nude mice
injected with HT-29 cells (white bar) and HT-29 cells stably expressing
dominant-negative STAT3 (grey bar). Closed and open circles represent the
measured sizes of the individual HT-29 and HT-29 STAT3 d.n. tumors,
respectively. Bars with standard errors represent average tumor sizes; P was
determined by Student’s t test. (B) (Inducible) STAT3 tyrosine phosphor-
ylation in cells before implantation into nude mice (left) and on development
of xenograft tumors after 21 days (right). Cells were optionally incubated with
10 ng/ml IL-6 for 30 minutes as indicated. After cell or tumor tissue lysis,
Western blot analysis was performed with antibody to phosphorylated STAT3
(top) or STAT3 (bottom), respectively. (C) Immunohistologic detection of
tyrosine-phosphorylated STAT3 in sections from HT-29 xenograft tumors
(left) and HT-29 STAT3 d.n. tumors (right).
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STAT3 (Figure 6B). These results show that the constitu-
tively active state of STAT3 in colon carcinoma cells is not
lost inevitably by cultivation, but can be restored by injecting
tumor cells into mice (Figure 6B). Similar observations were
made with xenografts derived from the implantation of COGA
1 cells (data not shown).
Suppression of STAT3 Activity in Colon Carcinoma
Xenograft Tumors Reduces Tumor Growth
To address directly in how far STAT3 activation influ-
ences the behavior of CRC cells in vivo, we tested the effect
of suppressing STAT3 function in xenografts. Both HT-29
cells and HT-29 cells stably expressing STAT3 d.n. were
implanted into mice to induce tumors. Aliquots of 105 cells
were injected subcutaneously into the necks and/or flanks
of nude mice. The numbers of injection sites were n = 7
for HT-29 cells and n = 15 for HT-29 STAT3 d.n. cells.
Within 3 weeks, tumors developed at 6 of 7 (HT-29), or 12
of 15 injection sites (HT-29 STAT3 d.n.), respectively.
Twenty-one days postinjection, animals were sacrificed,
tumors were explanted, and their respective sizes were
determined. As shown in Figure 7A, the average size of
HT-29 STAT3 d.n.–derived tumors (3 mm) was significantly
smaller compared to that of tumors originating from HT-29
parental cells (5.5 mm).
To confirm that this effect correlated with differences
in STAT3 activation, the level of STAT3 tyrosine phosphory-
lation in representative HT-29 and HT-29 STAT3 d.n. tumors
was analyzed. As shown in Figure 7B (right-hand side),
STAT3 activation in HT-29 STAT3 d.n. tumors was very low
compared to tumors originating from the parental cell line.
Obviously, the tumors had retained the original properties
of the cell lines, HT-29 and HT-29 STAT3 d.n., with regard
to inducible STAT3 activation (Figure 7B, left hand side).
Finally, we compared STAT3 activation in tumors from
HT-29 and HT-29 STAT3 d.n. cells by immunohistochemis-
try, employing an antibody to tyrosine-phosphorylated
STAT3 (Figure 7C). Whereas tumors derived from HT-29
cells were highly positive for phospho-STAT3 and showed a
strong signal accumulation in cell nuclei, tumors of HT-29
STAT3 d.n. cells showed only minor indications of STAT3
activation and no stained nuclei.
These results are highly suggestive for a prominent role of
STAT3 in the growth of xenograft colorectal tumors.
Discussion
STAT3 appears to be an important player in the pathogen-
esis of various human cancers. Like in a number of other
solid tumors, it is constitutively active in the large majority of
human colorectal cancer tissues.
Obviously, STAT3 may contribute to oncogenesis in the
colon epithelium by exerting a promoting effect on the cell
cycle. For colon carcinoma, this notion is supported by
the finding that heterologous overexpression of STAT3 or
cytokine-mediated activation of endogenous STAT3 in
colon carcinoma cell lines accelerates cell proliferation.
The effect is specific for colon cancer cells and certain
other transformed cell types such as, for example, glioblas-
toma cells [27] and squamous epithelial cells [39], but is not
universal because similar experiments with tumor cell lines
derived from the mammary gland did not result in compa-
rable enhancement of cell division (E.P., unpublished work).
Antiapoptotic signaling may also contribute to the effects
of inappropriate STAT3 function in colon carcinoma cells.
Preliminary experiments indicate an elevated abundance
level of Cyclin D1 and Bcl-2 protein in our tumor biopsies
compared to adjacent tissue (data not shown). In situ
techniques, however, are required to verify whether such
changes coincide spatially with STAT3 activity within the
heterogeneous tumor tissue. STAT3 activity may also be
associated with enhanced cell motility and invasiveness. It
is known that STAT3 deficiency in keratinocytes leads to
impaired motility and defects in wound healing [40], and we
have observed that overexpression of STAT3 in HT-29 cells
increases cell invasiveness in in vitro tests (S.A.T., unpub-
lished results).
Although aberrant STAT3 activity is now considered as
functionally important for the occurrence and/or mainte-
nance of various malignant tumors, it is poorly understood
by which mechanisms excessive STAT3 activity in cancer is
triggered. Unlike for other signaling molecules, no naturally
occurring genetic mutations or amplifications of STAT3
associated with oncogenesis have been identified so far
[41], indicating that persistent STAT3 activity is most prob-
ably due to dysregulated events upstream of STAT3 within
the signaling pathways (e.g., activation or mutation of phys-
iological STAT activators such as the Janus kinases). Alter-
natively, STAT3 activation in cancer could result from
overexpression of growth factors and their receptors, or
inhibition of negative regulators [13]. Various recent findings,
including our own, point to an important role of cytokines and
growth factors secreted by tumor cells.
In contrast to tumor cell lines originating from other
tumors, all colon carcinoma cell lines employed in our study
were negative for STAT3 activity in the absence of cytokine
stimulation. Interestingly, they showed profound activity on
implantation and xenograft tumor formation in immunodefi-
cient mice. We suggest that diffusible factors are responsible
for this phenomenon. Recent reports have identified auto-
crine loops involving factors that trigger JAK/STAT pathways
as crucial formalignant cell behavior in several tumormodels.
In breast carcinoma cells, the mechanism of autocrine-
mediated STAT3 activation, which correlates with cell prolif-
eration, has been identified [42]. In brain tumors, STAT3 is
considered to play a central role in autocrine activation of
the vascular endothelial growth factor (VEGF) system [22].
Different examples for IL-6–triggered autocrine stimulation
of tumor cells have been published recently such as acute
myeloid leukemia cells [43], as well as carcinoma cells of
the kidney [44] and the prostate [45]. It is up to future works to
identify the factors responsible for the activation of STAT3 in
CRC, and to exploit their potential suitability as diagnostic
markers or therapeutic targets.
In addition to the tumor biopsies, we also analyzed sev-
eral samples of non-neoplastic adjacent tissues obtained
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from the same patients and observed significant STAT3
activity in more than half of the cases (data not shown).
These findings suggest the possibility that STAT3 activation
may occur before histologic alterations of the intestinal tissue
become detectable, and are reminiscent of similar results
reported for prostate cancer [23].
CRC is a particularly well studied malignancy with regard
to genetic alterations involved in the process of oncogenesis.
Dysregulation of the Wnt signaling pathway is of major
importance for the development of the malignant cellular
phenotype: Mutations of APC or b-catenin cause permanent
stimulation of transcription factors, Tcf-4 and Lef-4 (reviewed
in Ref. [46]). It is interesting to note that STAT3 appears to
exert crosstalk with the Wnt pathway: Mutant APC [47] as
well as Tcf-4 and Lef-4 [48] are able to associate or coop-
erate with STAT3, raising the possibility that Tcf-4/Lef-4–
driven transcriptional promotion of the cell cycle through
c-myc or D-type cyclins [49] is modulated or enhanced by
STAT3. Cell lines HT-29 and COGA used in this study show
activated Wnt signaling due to mutations in APC and other
mediators [34,50], and are thus interesting model systems to
investigate the relationships between pathogenic STAT and
Wnt signal transduction in the context of CRC.
STAT3 has recently emerged as an attractive target
for tumor treatment. In cultured tumor cells, blockage of
STAT3 was found to downmodulate proliferation and to
induce programmed cell death. Transfection of a dominant-
negative form of STAT3 led to growth inhibition and apopto-
sis of breast, brain, and prostate cancer cells [14,27,41,51].
Most interestingly, growth of experimental melanomas could
be suppressed efficiently in mice by introduction of a func-
tionally deficient STAT3 variant [29]. Interruption of the
probable IL-6 autocrine loop in prostate cancer xenografts
by administration of a neutralizing anti– IL-6 antibody induced
tumor regression [52]. Our findings suggest that target-
ing STAT3 may also be an interesting option to fight CRC
and other cancers in which STAT3 activation is linked with
tumor progression.
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